Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A fluorescence sedimentation assay for dsDNA antibodies

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Managing patients on direct factor Xa inhibitors with rapid thrombelastography

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Plasma glycerol levels in men with hypertriglyceridemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Quantification of biotin in plasma samples by column switching liquid chromatography - tandem mass spectrometry

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Reference intervals for 12 clinical laboratory tests in a Danish population: The Lolland-Falster Health Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Breast cancer in systemic lupus

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The Farr assay is a radioimmunoassay (RIA) for dsDNA antibodies, based on antibody precipitation using ammonium sulphate and quantification using radio-labelled dsDNA. The RIA-Farr assay offers outstanding clinical specificity and sensitivity for systemic lupus erythematosus (SLE) compared to other assays but does also present some disadvantages as it utilizes radioactive-labelled dsDNA and requires high levels of technical expertise for safe handling. Here, a new precipitation assay, 'Fluoro-Farr' assay, is described. This assay maintains a high sensitivity and specificity for SLE but is based on precipitation with polyethylene glycol (PEG) and fluorescence of EvaGreen intercalated in dsDNA as detection principle. As dsDNA antibodies are quantified using fluorescence, the disadvantages of working with radioactivity are eliminated. The Fluoro-Farr assay was developed and validated, and the diagnostic efficiency of the assay was evaluated by testing 57 sera from SLE patients and 60 healthy controls. The Fluoro-Farr assay revealed a diagnostic sensitivity of 68% at a diagnostic specificity of 95% (ROC AUC 0.91). Furthermore, the new Fluoro-Farr assay was compared to the RIA-Farr assay, and showed a correlation of the outcomes from the two assays, but the Fluoro-Farr assay did not outperform the RIA-Farr assay due to its outstanding clinical diagnostic efficiency (ROC AUC 0.99). In conclusion, the Fluoro-Farr assay presents a viable alternative to the traditional RIA-Farr assay; especially in laboratories without facilities to perform assays with radioactivity-based read-out. As the RIA-Farr assay, the Fluoro-Farr assay has the advantage of being a precipitation assay allowing antibody:dsDNA interaction in solution using native dsDNA.

Original languageEnglish
JournalScandinavian Journal of Clinical and Laboratory Investigation
Volume77
Issue number6
Pages (from-to)465-471
Number of pages7
ISSN0036-5513
DOIs
Publication statusPublished - Oct 2017

    Research areas

  • Journal Article

ID: 52377264